Stocks to Watch for June 15: Vedanta, Aurobindo Pharma, JSW Energy, Dr Reddy's and more

JSW Energy Ltd | The company said its wholly owned subsidiary JSW Neo Energy Ltd has commissioned the full 150 MW capacity of the Tidong Power Generation Private Ltd hydroelectric project in Himachal Pradesh. With this commissioning, JSW Energy’s total installed capacity has increased to approximately 13,900 MW.

Aurobindo Pharma | Drug maker said the US Food and Drug Administration (US FDA) has classified the inspection of Eugia Pharma Specialities’ Unit-III facility as "Official Action Indicated" (OAI).

ONGC | State-run oil and gas producer Oil and Natural Gas Corporation Ltd (ONGC) on Friday (June 12) said its subsidiary ONGC Petro additions Ltd (OPaL) has approved a proposal to raise up to ₹4,471 crore through the private placement of non-convertible debentures (NCDs).

HPCL | Hindustan Petroleum Corporation Ltd. (HPCL) has fixed August 14, 2026 as the record date for its proposed final dividend of ₹19.25 per equity share for FY26, according to a company communication issued on Friday. The dividend remains subject to shareholder approval at the upcoming annual general meeting.

Power Grid | State-owned Power Grid Corporation of India Ltd (POWERGRID) on Friday (June 12) said it has been declared the successful bidder under tariff-based competitive bidding (TBCB) to establish an inter-state transmission system project in Andhra Pradesh.

Meesho | E-commerce firm announced the acquisition of Kirana Club Pte. Ltd and Retail Pulse Labs Private Ltd for an aggregate consideration of ₹202.08 crore, as part of its strategy to expand its presence in India’s digital commerce ecosystem.

SEPC Ltd | The company has received a Letter of Acceptance (LoA) from Steel Authority of India Ltd (SAIL) – IISCO Steel Plant (ISP), Burnpur, for works related to the 4.08 MTPA crude steel expansion project, according to an exchange filing.

Ipca Lab | Mumbai-based Ipca Laboratories and Bhami’s Research Laboratory (BRL) have entered into a definitive global licensing agreement that grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform.

Dr Reddy's Laboratories | The pharma major announced the launch of Bosutinib Tablets, which are used in the treatment of Chronic Myeloid Leukaemia (CML). The Hyderabad-based pharma company announced in an exchange filing that its Bosutinib Tablets 400mg, a generic equivalent of Bosulif, are in the United States.